pp-142 Inhalation solution
Dossier type
CTD
Dossier status
Under development
Country of origin
European Union
GMP approvals
EU GMP
Comments
Indication: Treatment-resistant depression (TRD; adults failing ≥2 antidepressants)
Clinical stage: Phase 2b
Modality: Small molecule (synthetic 5-MeO-DMT)
Mechanism / Target: 5-HT2A/2C agonist and sigma-1 receptor ligand — induces acute psychoplastogen effect promoting synaptic plasticity and rapid antidepressant neuroadaptation
Route / form: Inhalation solution (metered-dose inhaler; single or small number of clinic sessions)
Differentiation: Single-session treatment potential; faster onset vs ketamine/esketamine; inhaled route avoids IV; no dependency risk reported vs classic opioids; profound rapid antidepressant data
Manufacturer #39173
Clinical-stage psychiatry company developing single-session psychedelic medicines for TRD. Pioneers inhaled 5-MeO-DMT as a rapid-acting, clinic-based antidepressant treatment. Wholly owned pipeline advancing through Phase 2 in high unmet-need psychiatric indications.